Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
5.5200
-0.1300 (-2.30%)
NASDAQ · Last Trade: Nov 1st, 2:14 AM EDT
Detailed Quote
Previous Close
5.650
Open
5.700
Bid
5.510
Ask
5.520
Day's Range
5.410 - 5.736
52 Week Range
3.790 - 12.36
Volume
43,304,102
Market Cap
929.71M
PE Ratio (TTM)
-3.033
EPS (TTM)
-1.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
67,272,883
Chart
About Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development. By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need. Read More
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by industry observers like PharmTech.com, rapid workforce upskilling is no longer a luxury but a critical necessity for companies aiming to thrive in this new era. The immediate significance [...]
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to market. Driven by advanced data integration and sophisticated analytics, AI is dramatically accelerating timelines, reducing costs, and significantly improving success rates across the entire drug development pipeline. This paradigm [...]
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift towards personalized medicine. Artificial intelligence (AI) stands at the forefront of this revolution, offering unprecedented capabilities to overcome long-standing challenges and accelerate the delivery of tailored, effective treatments. [...]
The U.S. stock market has staged a remarkable recovery in October 2025, with major indices reclaiming lost ground amidst a confluence of positive corporate earnings and improving macroeconomic sentiment. However, a significant driver behind this upward trajectory isn't just institutional buying; it's a dramatic surge in heavily-shorted stocks, igniting
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
The pharmaceutical industry stands on the precipice of a revolutionary transformation, driven by the burgeoning power of artificial intelligence (AI) agents. These sophisticated, autonomous systems are rapidly redefining the drug discovery process, moving beyond mere data analysis to actively generating hypotheses, designing novel molecules, and orchestrating complex experimental workflows. As of October 2025, AI agents [...]
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to market. By combining generative artificial intelligence with high-throughput wet lab technologies, Absci aims to drastically cut down the time and cost associated
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?
On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the S&P 500 slipping nearly 0.6% to 6,753.72. The Dow Jones Industrial Average was unchanged at 46,601.78.These are the top stocks that gained the attention of retail traders and investors through the day:
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This transformative shift is redefining traditional workflows, demanding a radical re-evaluation of skill sets, and igniting critical discussions around ethics, regulation, and the very
